Premium
Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria
Author(s) -
Le Jennifer,
Ashley Elizabeth Dodds,
Neuhauser Melinda M.,
Brown Jack,
Gentry Chris,
Klepser Michael E.,
Marr Ann Marie,
Schiller Daryl,
Schwiesow Joshua N.,
Tice Sally,
VandenBussche Heather L.,
Wood G. Christopher
Publication year - 2010
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.30.6.562
Subject(s) - intensive care medicine , medicine , aerosolization , guideline , antimicrobial , cystic fibrosis , pneumonia , dosing , pharmacotherapy , antibiotics , pharmacology , inhalation , pathology , chemistry , organic chemistry , biology , microbiology and biotechnology , anatomy
Aerosolized delivery of antimicrobial agents is an attractive option for management of pulmonary infections, as this is an ideal method of providing high local drug concentrations while minimizing systemic exposure. With the paucity of consensus regarding the safety, efficacy, and means with which to use aerosolized antimicrobials, a task force was created by the Society of Infectious Diseases Pharmacists to critically review and evaluate the literature on the use of aerosolized antiinfective agents. This article summarizes key findings and statements for preventing or treating a variety of infectious diseases, including cystic fibrosis, bronchiecstasis, hospital acquired pneumonia, fungal infections, nontuberculosis mycobacterial infection, and Pneumocystis jiroveci pneumonia. Our intention was to provide guidance for clinicians on the use of aerosolized antibiotics through evidence based pharmacotherapy. Further research with well designed clinical trials is necessary to elucidate the optimal dosage and duration of therapy and, of equal importance, to appreciate the true risks associated with the use of aerosolized delivery systems.